NewAmsterdam Pharma says late-stage trial for cholesterol drug succeeded
Dutch biotech NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its oral anti-cholesterol therapy containing ...
FierceBiotech2d
NewAmsterdam’s cholesterol drug scores another phase 3 win—and disappoints investors again
NewAmsterdam, which reported another phase 3 win in July, plans to use the data to file for approval. However, as happened in ...
BioWorld2d
Newamsterdam’s obicetrapib combo nails phase III LDL-C endpoints
It all comes down to outcomes,” said Michael Davidson, CEO of Newamsterdam Pharma Co. NV, which hailed “robust” and “consistent” data from its phase III study testing a fixed-dose combination of CETP ...
Weight-loss drugs replacing some surgeries, but doctors say they're 'not a miracle drug'
Researchers looked at the health records of 17 million Americans with obesity and determined that between 2022 and 2023, ...
'Powerful' cholesterol-lowering spice doctor says is 'as effective as statins'
Dr Eric Berg DC, who is known as The Knowledge Doc, has shared the 'amazing benefits' of taking half a teaspoon of a superfood that reduces cholesterol and can be found in your kitchen cupboard ...
Too Old to Operate4d
Polypharmacy and Drug Effects on Aβ Fibrillation in Neurodegenerative Diseases
The following is a summary of “Highly prevalent geriatric medications and their effect on β-amyloid fibril formation,” ...
Seeking Alpha2d
NewAmsterdam Pharma says late-stage trial for cholesterol drug succeeded
Dutch biotech NewAmsterdam Pharma (NASDAQ:NAMS) announced Wednesday that its oral anti-cholesterol therapy containing experimental drugs obicetrapib and ezetimibe reached all co-primary endpoints ...